Tramiprosate clinical trials
How each study uses tramiprosate is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
4 studies that test it; most in 2004 (1)
| Year | Studies |
|---|---|
| 2004 | 1 |
| 2005 | 1 |
| 2006 | 1 |
| 2021 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 3 · Other 1
Bellus Health Inc. - a GSK company (3) · Aristotle University Of Thessaloniki (1)
Often tested with
Tested in the same studies.
Related medicines
As reviewed, each with the page that says it.
- One of GABA Agonists source
Studies
Open first, then newest update. How each study uses tramiprosate is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 4
- The Effects of Cannabidiol and Homotaurine in Patients With Mild Cognitive ImpairmentStatus unknownPhase 4Aristotle University Of ThessalonikiNCT05022186Written as HomotaurineHow we know
- European Study of 3APS in Mild to Moderate Alzheimer's Disease PatientsStatus unknownPhase 3Bellus Health Inc. - a GSK companyNCT00217763Written as 3APSHow we know
- Open-Label Extension of the Phase III Study With Tramiprosate (3APS) in Patients With Mild to Moderate Alzheimer's DiseaseStatus unknownPhase 3Bellus Health Inc. - a GSK companyNCT00314912Written as Tramiprosate (3APS)How we know
- Evaluation of 3APS in Patients With Mild to Moderate Alzheimer's DiseaseStatus unknownPhase 3Bellus Health Inc. - a GSK companyNCT00088673Written as 3APSHow we know
Codes
What other systems call tramiprosate · ClinicalTrials.gg INT002233
- MeSH (NLM) C001355tramiprosateConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) 5K8EAX0G53TRAMIPROSATEConfirmed FDA, NLM, Wikidata
- RxNorm 1374845Confirmed FDA, Wikidata
- Wikidata Q5891790tramiprosateConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C76786TramiprosateOne source FDA
- DrugBank DB06527One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C001355 | tramiprosate | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | 5K8EAX0G53 | TRAMIPROSATE | Confirmed FDA, NLM, Wikidata |
| RxNorm | 1374845 | — | Confirmed FDA, Wikidata |
| Wikidata | Q5891790 | tramiprosate | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C76786 | Tramiprosate | One source FDA |
| DrugBank | DB06527 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.